Project description
Real-time ablation monitoring improves the treatment of atrial fibrillation
Atrial fibrillation is associated with abnormal beating of the heart, which can lead to blood clots and cause ischaemia or stroke. As a treatment, an ablative procedure is usually employed to scar the heart tissue that exhibits aberrant electrical signalling. The EU-funded VERAFEYE project is working on a novel smart catheter system that provides real-time tissue analysis and navigation during ablation. This allows surgeons to analyse the progress of the surgery in real time and correct or enhance the treatment accordingly. The novel system will prevent repetitive surgeries and ensure that success is based on evidence rather than solely on the experience of the surgeon.
Objective
OneProjects is a new medical device company based in Dublin and Munich developing the new wave of disruptive cardiac imaging
innovations that will provide a sea change in the treatment of atrial fibrillation (AFib) through ablation. With the clinical need at the
core of our mission and world-class expertise in medical imaging and product commercialisation, OneProjects is developing
VERAFEYE, a novel smart catheter system that provides real-time 4D ablation/tissue analysis and navigation enabled through
advanced imaging and analytics.
VERAFEYE is a breakthrough connected technology which can generate unprecedented 4D data during the ablation procedure, thus
providing the physician with real-time analysis of the surgery. VERAFEYE will for the first time allow clinicians to correct and enhance
the treatment in the 1st procedure, ensuring the patient is AFib free, and hence remove the need for multiple surgeries. VERAFEYE
will shift treatment to the era of evidence- and data-based success rather than purely relying on the experience of the
electrophysiologist as is currently the case.
Fields of science
Keywords
Programme(s)
Funding Scheme
SME-2 - SME instrument phase 2Coordinator
D04K5D0 CLONSKEAGH DUBLIN
Ireland
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.